Article: Regulatory guidance in designing a CCI testing strategy
Posted: 6 January 2021 | Lighthouse Instruments | No comments yet
A summary of the current state of container closure integrity testing in the pharmaceutical industry.
Container closure integrity (CCI) plays an important role in maintaining the sterility and stability of sterile injectable products. Recent regulatory guidance has triggered changes in industry best practices in the area of CCI testing. This article summarizes the current state of container closure integrity testing in the pharmaceutical and biopharmaceutical industries and outlines possible approaches for developing a CCIT strategy.
Related content from this organisation
- Article: A holistic strategy to ensure CCI of sterile vials
- Whitepaper: Nondestructive moisture analysis of lyophilised product
- Case study: Oxygen monitoring during shelf life
- Application note: In-process monitoring of headspace oxygen levels
- A holistic strategy to ensure container closure integrity of sterile vials
Related topics
Analytical techniques, Biologics, Biopharmaceuticals, Biosimilars, Formulation, Freeze Drying, Gene therapy, Manufacturing, QA/QC, Research & Development (R&D), Vaccines
